Lee Financial’s Ascendis Pharma A/S ASND Stock Holding History

Lee Financial’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-69	Closed	-$9K	–	772
2021 Q4	$9K	Buy	+69	New	+$10.3K	﹤0.01%	511

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lee Financial's ASND Position: Q1 2022 in Review

Lee Financial sold out of Ascendis Pharma A/S (ASND) in Q1 2022, closing a stake of 69 shares — an estimated $9K sold.

Lee Financial first reported a position in ASND in Q4 2021 and held it in 1 quarter. The position peaked at $9K in Q4 2021. 178 funds tracked by Wall St. Rank hold ASND as of Q1 2022.

Lee Financial reported no remaining Ascendis Pharma A/S position as of Q1 2022 after selling out during the quarter.
Lee Financial sold 69 Ascendis Pharma A/S shares in Q1 2022, an estimated $9K.
Lee Financial first reported a position in Ascendis Pharma A/S in Q4 2021 and held it in 1 quarter.
Lee Financial's Ascendis Pharma A/S position peaked at $9K in Q4 2021.
178 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2022.

Based on Lee Financial's 13F filing for Q1 2022, filed 11 May 2022.